MedTrace Logo

A Study of IBI362 in Chinese Patients With Type 2 Diabetes

NCT04965506 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 252

Last updated 2023-12-27

No results posted yet for this study

Summary

The purpose of this study is to evaluate the efficacy and safety of IBI362 in Chinese patients with Type 2 Diabetes.

Conditions

Interventions

DRUG

IBI362

IBI362 administered subcutaneously (SC) once a week.

OTHER

placebo

placebo administered subcutaneously (SC) once a week.

OTHER

Dulaglutide

Dulaglutide administered subcutaneously (SC) once a week.

Sponsors & Collaborators

  • Innovent Biologics (Suzhou) Co. Ltd.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-09-06
Primary Completion
2022-04-28
Completion
2022-06-11

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04965506 on ClinicalTrials.gov